BiotechTube

AQUAVAN (fospropofol disodium; GPI 15715 )

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postoperative Sedation

Conditions

Postoperative Sedation, Intubation, Respiration, Artificial

Trial Timeline

Jul 1, 2005 → May 1, 2007

NCT ID
NCT00125398

About AQUAVAN (fospropofol disodium; GPI 15715 )

AQUAVAN (fospropofol disodium; GPI 15715 ) is a phase 2 stage product being developed by Eisai for Postoperative Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT00125398. Target conditions include Postoperative Sedation, Intubation, Respiration, Artificial.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00125398Phase 2Completed

Competing Products

20 competing products in Postoperative Sedation

See all competitors
ProductCompanyStageHype Score
Naldemedine + PlaceboShionogiPhase 2
52
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
85
Lemborexant 5 mg + Control (placebo) groupEisaiPhase 2
52
Ondansetron + PalonosetronEisaiPhase 2
52
ONO-1101Ono PharmaceuticalPhase 2
52
ONO-1101Ono PharmaceuticalPhase 2/3
65
Levofloxacin Ophthalmic + CefuroximeSanten PharmaceuticalPhase 1/2
41
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic SolutionSanten PharmaceuticalPhase 1/2
41
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
33
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
77
SHR8554 InjectionJiangsu Hengrui MedicinePhase 1
33
EsomeprazoleAstraZenecaApproved
85
deep neuromuscular blockMerckPre-clinical
23
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + PlaceboMerckPhase 2
52
MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
77
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
85
MK0719MerckPhase 2
52
Sugammadex + NeostigmineMerckApproved
85
MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3
77
MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3
77

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85